Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors...
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...
By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry
Launch expands Niagen ® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation
Niagen Bioscience: Q4 Earnings Snapshot
Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END
Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities
Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers